Compare BCTXZ & EICA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BCTXZ | EICA |
|---|---|---|
| Founded | N/A | N/A |
| Country | Canada | |
| Employees | 4 | N/A |
| Industry | | Finance/Investors Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2021 |
| Metric | BCTXZ | EICA |
|---|---|---|
| Price | $0.08 | $25.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 87.7K | 2.9K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $24.10 |
| 52 Week High | $1.14 | $25.92 |
| Indicator | BCTXZ | EICA |
|---|---|---|
| Relative Strength Index (RSI) | 37.77 | 55.40 |
| Support Level | $0.06 | $24.56 |
| Resistance Level | $0.11 | $25.08 |
| Average True Range (ATR) | 0.01 | 0.06 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 67.12 | 38.92 |
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.